It is worth noting that there are no marketed PDE4D subtype-selective inhibitors, and BPN14770, an allosteric inhibitor of PDE4D, is being studied in the context of cognitive function and other brain disorders, but still exhibits some inevitable side effects17, 18. Here, PDE4D is linked to brain disorder.